Staidson Beijing Biopharmaceuticals Co Ltd., a prominent player in the health care sector, has been making significant strides in the pharmaceutical industry. As a company operating under the Shenzhen Stock Exchange, Staidson BIO has established itself as a key entity in the development and distribution of biological products within China. Founded in 2002 and headquartered in Beijing, the company has been dedicated to advancing health care through its innovative product offerings.
Staidson BIO’s product portfolio is diverse, focusing on both innovative and essential pharmaceuticals. Among its notable products are su peptide, an injection of mouse nerve growth factor, which is pivotal in nerve regeneration research. Additionally, the company offers Shu Tai Qing, a polyethylene glycol electrolyte powder designed to address bowel and constipation issues. For patients dealing with overactive bladder, Staidson BIO provides Shu Wei Yan, a trospium chloride capsule. The company also supplies a range of other medications, including aspirin enteric-coated tablets, gliclazide tablets, and nabumetone capsules, catering to various therapeutic needs.
Financially, Staidson BIO has experienced fluctuations in its market performance. As of May 5, 2026, the company’s close price stood at 28.81 CNY. Over the past year, the stock has seen a 52-week high of 66.66 CNY on August 18, 2025, and a low of 9.9 CNY on May 11, 2025. Despite these variations, the company maintains a substantial market capitalization of 13,760,000,000 CNY. However, the price-to-earnings ratio is notably negative at -144.85, indicating challenges in profitability or accounting adjustments that may affect earnings.
Staidson BIO’s journey to its current status began with its Initial Public Offering (IPO) on April 15, 2011. Since then, the company has expanded its reach and solidified its position in the pharmaceutical landscape. For more information, stakeholders and interested parties can visit the company’s website at www.staidson.com .
As Staidson BIO continues to navigate the complexities of the pharmaceutical industry, its commitment to research and development remains a cornerstone of its strategy. The company’s focus on producing high-quality biological products underscores its dedication to improving health care outcomes in China and beyond.
